Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Integrated Research Limited ( (AU:IRI) ) has issued an update.
Integrated Research reported a 2% decline in first-half FY26 revenue to $28.3m and an EBITDA loss of $3.1m, largely due to higher expected credit losses and a softer renewals book, despite a solid 8% increase in cash to $43.6m. Management highlighted that profit will remain pressured in the short to medium term as the company continues substantial investment in new products under its product-led growth strategy.
The group accelerated new product delivery, launching Iris, a natural-language AI observability interface, Elevate, a cloud-based Prognosis-as-a-service offering, and completing the first implementation of its High Value Payments solution with a top-10 U.S. bank. New business indicators showed early traction, with new client licence revenue up 12% and expansion licence revenue up 110%, positioning IR for a gradual shift toward sustainable, consumption-based growth despite near-term earnings headwinds.
The most recent analyst rating on (AU:IRI) stock is a Hold with a A$0.34 price target. To see the full list of analyst forecasts on Integrated Research Limited stock, see the AU:IRI Stock Forecast page.
More about Integrated Research Limited
Integrated Research Limited (IR) is an ASX-listed provider of observability solutions for business-critical IT ecosystems, focusing on real-time performance intelligence across complex, AI-enabled enterprise environments. Its core offerings include Prognosis and newly launched cloud and AI interfaces aimed at sectors such as government, health, defence and global financial institutions.
Average Trading Volume: 148,148
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$56.89M
For an in-depth examination of IRI stock, go to TipRanks’ Overview page.